Is there a role for a vaccine in leprosy control?

Leprosy Review

Volumn 78, Issue 4, 2007, Pages 338-342

  Gillis, Thomas ^a,b  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; LEPROSY VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 CD8 RATIO; DISEASE TRANSMISSION; GRANULOMATOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEPROSY; LEPROSY CONTROL; MYCOBACTERIUM LEPRAE; NEUROPATHY; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; VACCINATION;

BACTERIAL VACCINES; HUMANS; LEPROSY; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 38649129853     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Adams JE, Pena MT, Gillis TP et al. Expression of nine-banded armadillo (Dasypus novemcinctus) interleukin-2 in E. coli. Cytokine, 2005; 32: 219-225.
2. Anonymous. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational guidelines. Lepr Rev, 2006; 77(IX, X): 1-50. (Notes: Corporate Name: World Health Organization Regional Office for South-East Asia New Delhi).
3. Baumann S, Nasser Eddine A, Kaufmann SH. Progress in tuberculosis vaccine development. Curr Opin Immunol, 2006; 18: 438-448.
4. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA, 1994; 271: 698-702.
5. Cunha SS, Dourado I, Barreto ML et al. Design of the leprosy component of the Brazilian BCG revaccination trial for assessing BCG effectiveness against leprosy in school children. Int J Lepr Other Mycobact Dis, 2004; 72: 8-15.
6. Cunha SS, Rodriguez LC, Pedrosa V et al. Neonatal BCG protection against leprosy: a study in Manaus, Brazilian Amazon. Lepr Rev, 2004; 75: 357-366.
7. De Sarkar A, Kaur I, Radotra BD, Kumar B. Impact of combined Mycobacterium w vaccine and 1 year of MDT on multibacillary leprosy patients. Int J Lepr Other Mycobact Dis, 2001; 69: 187-194.
8. Groathouse NA, Amin A, Marques MA et al. Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles. Infect Immun, 2006; 74: 6458-6466.
9. Hesseling AC, Marais BJ, Gie RP et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine, 2007; 25: 14-18.
10. Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet, 1996; 348: 17-24.
11. Lwin K, Sundaresan T, Gyi MM et al. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull World Health Organ, 1985; 63: 1069-1078.
12. Marques MA, Espinosa BJ, Xavier da Silveira EK et al. Continued proteomic analysis of Mycobacterium leprae subcellular fractions. Proteomics, 2004; 4: 2942-2953.
13. Pönnighaus JM, Fine PEM, Sterne JA et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet, 1992; 339: 636-639.
14. Scollard DM, Adams LB, Gillis TP et al. The continuing challenges of leprosy. Clin Microbiol Rev, 2006; 19: 338-381.
15. Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect Dis, 2006; 6: 162-170.
16. Williams DL, Torrero M, Wheeler PR et al. Biological implications of Mycobacterium leprae gene expression during infection. J Mol Microbiol Biotechnol, 2004; 8: 58-72.
17. Zaheer SA, Mukherjee R, Ramkumar B et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis, 1993; 167: 401-410.